PharmaCyte Biotech Inc - Asset Resilience Ratio
PharmaCyte Biotech Inc (PMCB) has an Asset Resilience Ratio of 39.52% as of April 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PharmaCyte Biotech Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2026)
This chart shows how PharmaCyte Biotech Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PMCB current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down PharmaCyte Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore PharmaCyte Biotech Inc (PMCB) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.48 Million | 39.52% |
| Total Liquid Assets | $18.48 Million | 39.52% |
Asset Resilience Insights
- Very High Liquidity: PharmaCyte Biotech Inc maintains exceptional liquid asset reserves at 39.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PharmaCyte Biotech Inc Industry Peers by Asset Resilience Ratio
Compare PharmaCyte Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for PharmaCyte Biotech Inc (2009–2026)
The table below shows the annual Asset Resilience Ratio data for PharmaCyte Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-04-30 | 39.52% | $18.48 Million | $46.75 Million | +38.86pp |
| 2025-04-30 | 0.66% | $366.32K | $55.17 Million | -- |
| 2024-04-30 | 0.00% | $0.00 | $59.90 Million | -- |
| 2020-04-30 | 25.50% | $1.57 Million | $6.17 Million | +24.98pp |
| 2009-04-30 | 0.52% | $31.18K | $6.04 Million | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more